EADO - European Association of Dermato-Oncology

Startseite
Schweiz
Zürich
EADO - European Association of Dermato-Oncology

The EADO is a non-profit association dedicated to promote, coordinate and improve clinical and labor

04/09/2026

Updates on the EADO Melanoma Guidelines… are you ready for 2027 News? 👀

🎫 Secure your ticket now for the 23rd EADO CONGRESS 2027 in Vienna, Austria 🇦🇹

🔗 LINK IN BIO

27/08/2026

When you should go for a dermatologic screening? Dr. tells us more about it 👀

12/08/2026

How should we interpret clinical trial data in melanoma?

Prof. Paolo Ascierto highlights an essential point: clinical trials generate crucial evidence, but they are conducted in highly selected patient populations. Strict inclusion criteria mean that some patients we routinely see in clinical practice, such as those with brain metastases, leptomeningeal disease or poorer performance status, may be underrepresented or excluded.

For this reason, trial results should never be viewed as simply “positive” or “negative.” They need to be interpreted in the context of the study design, inclusion criteria, assumptions, strengths and limitations.

Looking beyond the headline result, and critically examining what the data can and cannot tell us, is key to translating evidence into real-world clinical practice.

28/07/2026

🧬 Artificial Intelligence & Digital Diagnosis in Skin Cancer
Prof. Dr. Josep Malvehy, President of EADO, shares key highlights from his session at the 22nd EADO Congress in Prague on the latest digital technologies transforming skin cancer diagnosis! 🔬💡

Key takeaways on how AI and digital devices are changing dermato-oncology:

✨ Early Diagnostic Devices & AI: Integrating software, dermoscopy, and AI tools to predict risk and metastatic disease directly in clinical settings.

✨ 3D & 2D Avatars: Promising tools for deep phenotyping and personalized patient risk predictions.

✨ Multimodal AI & “Deep Imaging”: Combining image analysis with clinical, genetic, phenotypic, and omics data to improve diagnosis accuracy and precision management.

✨ Human-AI Collaboration: Combining expert clinical intuition with AI capability to drive the best outcome for skin cancer patients.

📲 Stay tuned for more exclusive video clips, session recaps, and updates from the 22nd EADO Congress!

Don’t get left behind—mark your calendars for the 23rd EADO Congress in Vienna (April 15–17, 2027)!

Get ready for ground-breaking science, international networking, and the future of dermato-oncology. See you in Vienna! 🇦🇹✨

DermatoOncology SkinCancer Melanoma DigitalDiagnosis AIinDermatology Dermatology JosepMalvehy MedicalInnovation

17/07/2026

Why do melanoma liver metastases present such a profound therapeutic challenge? 🧬
During the 22nd EADO Congress in Prague, Prof. Dr. Ines Pires da Silva shared pivotal insights into the distinct characteristics of the liver’s tumor microenvironment.

Her research highlights how this specific environment differs fundamentally from lung or bone metastases, frequently driving resistance to standard immunotherapy—a critical limitation in current clinical practice.

Understanding these organ-specific mechanisms is a vital step toward overcoming resistance and optimizing patient outcomes.

👀 Stay tuned to our profile. Over the coming weeks, we will be releasing exclusive video highlights, key session summaries, and major scientific updates from the Prague congress.

📍 Save the Date: EADO 2027 — Vienna, Austria 🇦🇹

Plan ahead to join leading global experts and secure your place at the forefront of skin cancer research.
🔗 LINK IN BIO

09/07/2026

What are the major shifts happening in cutaneous squamous cell carcinoma (cSCC) today? At the 22nd EADO Meeting in Prague, Prof. Dr. Javier Cañueto (University Hospital of Salamanca, Spain) shared key insights on how management strategies are evolving:

•Risk Stratification: Combining risk factors is crucial to stratify patients accurately.

•Personalized Assessments: Nomograms and gene expression panels are providing a more tailored risk assessment for patients.

•Treatment Roles: While surgery remains the cornerstone of management, adjuvant radiation therapy continues to play an important role.

•Advanced Imaging: Staging and imaging are evolving, with nodal staging becoming more widely used, especially in baseline cSCC management.

✨ Stay Tuned! We will be sharing more exclusive highlights, videos, and expert updates from Prague 2026 over the coming weeks.

🇨🇭 Don’t want to miss the next big conversation in dermato-oncology? Start planning ahead! The 23rd EADO Congress will take place next year in Vienna, 2027. Mark your calendars—you won’t want to miss it!

02/07/2026

🧬 Advancing CAR T-Cell Therapy in Cutaneous Malignancies 🧬
Prof. Dr. Ugur Uslu (University of Würzburg, Germany) discusses the current landscape and future directions of CAR T-Cell therapy for skin cancer.

While CAR T-cell therapy has demonstrated remarkable efficacy in hematological malignancies, its application in solid tumors remains a critical research frontier.

Prof. Dr. Uslu highlights that while current treatment options for advanced melanoma are promising, approximately half of these patients either do not respond or eventually experience a long-term relapse.

To address this unmet clinical need, his laboratory is actively developing new CAR constructs specific for antigens against melanoma and Merkel cell carcinoma.

By exploring combination therapies—such as combining CAR T-cells with checkpoint blockade or oncolytic viruses—and engineering cells to secrete cytokines or antibodies, the goal is to optimize efficacy and rapidly transition these advancements into early-phase clinical trials.

📅 Looking Ahead: The global discussion on dermato-oncology innovation continues next year. Secure your place at the forefront of skin cancer research—join us for the 23rd EADO Congress in 2027 in Vienna, Austria. 🇦🇹

27/06/2026

Prof. Dr. Piotr Rutkowski (Warsaw, Poland) discusses the rapidly evolving management landscape for Merkel Cell Carcinoma (MCC)—a rare and highly aggressive skin tumor.

Historically, therapeutic options beyond classic surgery and radiotherapy were limited.

Today, contemporary strategies aim to refine patient management, optimize treatment de-escalation, and significantly improve cure rates.

📲Follow our page and enable notifications to receive all upcoming video highlights, abstract summaries, and clinical updates from the 22nd EADO Meeting.

👉Advance your professional planning: the 23rd EADO Congress will take place next year in Vienna, Austria (2027)📆. Join the global dermato-oncology community to discuss the next wave of dermatological breakthroughs.

🔗 LINK IN BIO

12/06/2026

We had the privilege of speaking with Prof. Dr. Dagmar Whitaker from South Africa, who highlighted the critical balance between cutting-edge oncological advancements and global healthcare accessibility.

While the last decade has brought remarkable research breakthroughs and innovative therapies for previously untreatable diseases, these advanced protocols come with significant economic barriers.

For many regions worldwide, including South Africa, access to these expensive therapies remains limited.

As Prof. Dr. Whitaker emphasizes, our most effective strategy remains rooted in public education, proactive prevention, and early clinical detection.

Identifying melanoma at an early stage allows for straightforward surgical intervention, eliminating the need for complex and costly systemic treatments.

👉Follow to receive all subsequent video releases, expert presentations, and scientific updates from the Prague 2026 congress.

📆Join Us Next Year: The global dermatological community will reconvene for the 23rd EADO Congress in Vienna, 2027. Mark your calendars and prepare to join the vanguard of skin cancer research and education.

Adresse

Max-Högger-Strasse 6
Zürich
8048

Webseite

http://www.eado.org/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von EADO - European Association of Dermato-Oncology erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.